JAG1 and prostate carcinoma: In this study, we found that the overexpression of the processed intracellular domain of JAG1 (JICD) increased the expression of AR-Vs in prostate cancer (PC) cells and enhanced the transactivation of ARs in an androgen-independent as well as androgen-dependent manner.